Veeda Clinical Research Limited Shares

Veeda Clinical Research Limited Shares Price

₹5200M

Checking authentication...

Veeda Clinical Research Limited Shares

Phone

About Share

Veeda Clinical Research Limited Shares

Veeda Clinical Research Limited is one of the largest independent full-service clinical research organizations (CRO) in India. Established in 2004, the company has grown significantly, providing a broad range of clinical research solutions to the pharmaceutical industry globally.

Fundamentals

NameVeeda Clinical Research Limited Shares

Price₹535

Lot Size100

52 Week High₹550

52 Week Low₹525

DepositoryNSDL& CDSL

PAN NumberAACCC3633Q

ISIN NumberINE01HQ01026

CINU73100GJ2004PLC044023

RTA-

Market Cap (in cr)₹3072.0

P/E Ratio73.15

P/B Ratio6.61

Debt to Equity0.1

ROE (%)9.08

Book Value₹82.4

Face Value₹2

Valuation-

Total Shares56366796

Financial (In Cr)

Shareholding Pattern

Promoters

FAQ's

Our Blogs

Our blog provides insightful information about unlisted shares, offering a deeper understanding of how these assets work, their potential benefits, and the risks involved. Whether you're new to unlisted shares or looking to expand your knowledge, we cover topics such as investment strategies, valuation methods, market trends, and regulatory aspects. Stay updated with expert tips and guides to navigate the unlisted share market effectively.

OYO Unlisted Share Price: Latest Trends & Insights

Explore the latest OYO unlisted share price trends and valuation insights. Stay informed to make smart investment decisions today.

Bootes Impex Tech Ltd: Pre-IPO Analysis, and Strategic Implications

Bootes Impex Tech Ltd is preparing for an IPO, aiming to raise ₹1,000–1,500 crore to expand sustainable infrastructure and R&D. While the IPO presents strong growth potential, risks around execution, valuation, and market dynamics must be carefully managed.

Bootes Impex Tech Ltd Investment Guide: Opportunities and Risks

Bootes Impex Tech Ltd offers a compelling investment opportunity in the net-zero construction sector, backed by proprietary technologies, a strong order book, and alignment with India's sustainability vision. However, investors must consider risks like liquidity constraints, execution challenges, and regulatory uncertainties due to its unlisted status and industry complexities.